Brandon Scalea

Articles

NETs Treatment Arsenal Expands, With More Progress on the Horizon

May 1st 2019

Lowell B. Anthony, MD, FACP, sheds light on important data that have shaped the current neuroendocrine tumors treatment paradigm and highlights notable ongoing studies.

MCL Treatment Paradigm Expands With Novel Combos

May 1st 2019

Timothy Fenske, MD, MS, discusses promising ongoing research in mantle cell lymphoma that will look to further advanced the evolving paradigm.

Treatment Options Expanding for Benign Hematologic Disorders

April 30th 2019

Nathan T. Connell, MD, MPH, shares key updates in the rapidly evolving treatment paradigms of benign hematologic disorders.

Ongoing Research Builds Upon Advances in Stage III NSCLC, ALK+ Disease

April 27th 2019

Ronan J. Kelly, MD, MBA, addresses the paradigm shift in stage III unresectable non–small cell lung cancer before delving into the complex field of ALK-rearranged disease.

Chemoimmunotherapy Emerges as Frontline Standard in Squamous NSCLC

April 25th 2019

Eric S. Nadler, MD, discusses key data with immunotherapy in the treatment of patients with metastatic squamous non–small cell lung cancer.

Liquid Biopsy Screening Protocol Aims to Identify Actionable Targets in mCRC

April 24th 2019

Kristen Ciombor, MD, MSCI, discusses the promise of liquid biopsies in the rapidly evolving metastatic colorectal cancer paradigm and the potential implications of the COLOMATE trial.

IFN-Gamma Signature Not Linked to Durvalumab/Tremelimumab Benefit in Gastric Cancer

April 23rd 2019

Geoffrey Y. Ku, MD, discusses data of durvalumab plus tremelimumab in a biomarker-selected patient population and sheds light on the role of immunotherapy in patients with advanced gastric cancer.

SM-88 May Fill Unmet Need in Pancreatic Cancer

April 22nd 2019

Marcus Smith Noel, MD, discusses the early promise of SM-88 in the metastatic pancreatic cancer treatment landscape.

Tailored Approaches Offer Curative Potential to CRC Subsets

April 19th 2019

Michael J. Overman, MD, discusses an immunotherapy combination regimen in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.

Gomella Calls for Increased Genetic Testing in Prostate Cancer

April 18th 2019

Leonard G. Gomella, MD, underscores the need for genetic testing in prostate cancer, sheds light on important biomarkers in the space, and explains how these tests are helping oncologists facilitate a precision medicine approach.

Amid Advances, Obstacles Remain in Small Cell Lung Cancer

April 17th 2019

Aaron S. Mansfield, MD, discusses recent progress in small cell lung cancer and remaining challenges in the field.

Biomarkers Needed to Refine Use of Novel Combos in mRCC

April 17th 2019

Neeraj Agarwal, MD, discusses the recent encouraging data reported in mRCC and highlighted the next steps needed to move the needle forward in this space.

Figlin Highlights Immunotherapy Developments in RCC

April 15th 2019

Robert A. Figlin, MD, highlights advances made with immunotherapy in renal cell carcinoma and sheds light on the challenges that remain.

Sequist Sheds Light on Osimertinib/Savolitinib Combo in MET-Amplified NSCLC

April 10th 2019

Lecia V. Sequist, MD, highlights the expansion cohort data from the TATTON study and explains how these findings could impact the treatment landscape of EGFR-mutant NSCLC.

HER2+ Breast Cancer Paradigm Evolving With Practice-Changing New Options

April 9th 2019

Mark D. Pegram, MD, highlights data from pivotal studies that have helped to shape the current landscape of HER2-positive breast cancer and sheds light on emerging agents that are showing promise in the pipeline.

Genetic Testing Essential to Advancing Pancreatic Cancer Paradigm

April 9th 2019

Margaret A. Tempero, MD, discusses the impact of FOLFIRINOX in the treatment of patients with metastatic pancreatic cancer and sheds light on the importance of molecular profiling in the space.

Enzalutamide/Docetaxel Combo Improves PFS, But Not OS in Frontline mCRPC

April 8th 2019

Orazio Caffo, MD, discusses the CHEIRON trial findings and their implications on the treatment paradigm in metastatic castration-resistant prostate cancer.

Lutathera Fills Unmet Need in NETs, Role of Radiation Expands Across GI Cancers

April 5th 2019

Derek R. McHaffie, MD, discusses the role of radiation therapy in the treatment of gastrointestinal cancers and the impact of radionuclide therapy in patients with neuroendocrine tumors.

Challenges Remain Amid Advances in RCC and Prostate Cancer

April 5th 2019

David I. Quinn, PhD, MBBS, discusses the molecular diagnosis of renal cell carcinoma and also highlights emerging therapies in the treatment of patients with different subtypes of prostate cancer.

Progress in Relapsed/Refractory CLL Could Pave Way for Upfront Advances

April 3rd 2019

Joseph D. Rosenblatt, MD, discusses how advances made in chronic lymphocytic leukemia are changing the outlook for patients and predicts what can be accomplished in the near future.